The anti-inflammatory effect of milk and dairy products on periodontal cells: an in vitro approach

Panahipour, Layla; Nasserzare, Shayesteh; Amer, Zeinab; Brücke, F. Th. v.; Stähli, Alexandra; Kreissl, Alexandra; Haiden, Nadja; Gruber, Reinhard

doi:10.1007/s00784-018-2642-4

Cited by 23 publications

(27 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study showed that the highest concentrations of the pro-inflammatory cytokines IL-6 and IL-17 were found in the colon tissue of animals subjected to DMH treatment only (GNI group), whereas the intervention with the probiotic candidate L. paracasei DTA81 reduced significantly the levels of both cytokines. Milk intake also promoted a beneficial anti-inflammatory effect in the colon, which is in consonance with previously published studies [49][50][51][52][53][54]. It is well established that IL-6 and its overexpression has a detrimental role in early CRC tumorigenesis by promoting tumor growth and invasion [55].…”

Section: Discussionsupporting

confidence: 88%

Chemoprevention of DMH-Induced Early Colon Carcinogenesis in Male BALB/c Mice by Administration of Lactobacillus Paracasei DTA81

et al. 2020

View full text Add to dashboard Cite

We evaluated the effects of the probiotic candidate Lactobacillus paracasei DTA81 (DTA81) on liver oxidative stress, colonic cytokine profile, and gut microbiota in mice with induced early colon carcinogenesis (CRC) by 1,2-dimethylhydrazine (DMH). Animals were divided into four different groups (n = 6) and received the following treatments via orogastric gavage for 8 weeks: Group skim milk (GSM): 300 mg/freeze-dried skim milk/day; Group L. paracasei DTA81 (DTA81): 3 × 109 colony-forming units (CFU)/day; Group Lactobacillus rhamnosus GG (LGG): 3 × 109 CFU/day; Group non-intervention (GNI): 0.1 mL/water/day. A single DMH dose (20 mg/kg body weight) was injected intraperitoneally (i.p), weekly, in all animals (seven applications in total). At the end of the experimental period, DTA81 intake reduced hepatic levels of carbonyl protein and malondialdehyde (MDA). Moreover, low levels of the pro-inflammatory cytokines Interleukin-6 (IL-6) and IL-17, as well as a reduced expression level of the proliferating cell nuclear antigen (PCNA) were observed in colonic homogenates. Lastly, animals who received DTA81 showed an intestinal enrichment of the genus Ruminiclostridium and increased concentrations of caecal acetic acid and total short-chain fatty acids. In conclusion, this study indicates that the administration of the probiotic candidate DTA81 can have beneficial effects on the initial stages of CRC development.

show abstract

Section: Discussionsupporting

confidence: 88%

Chemoprevention of DMH-Induced Early Colon Carcinogenesis in Male BALB/c Mice by Administration of Lactobacillus Paracasei DTA81

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Disease relapse was not associated with dairy intake [75] and as an animal protein source, dairy was not associated with the risk on IBD [56]. Recently, yoghurt, buttermilk and fermented milk have demonstrated an anti-inflammatory effect in vitro [76]. Avoidance of dairy leads to increased risk of low calcium levels and osteoporosis [77], as commonly seen in 20-50% of the IBD patients already [70].…”

Section: Discussionmentioning

confidence: 99%

Habitual dietary intake of IBD patients differs from population controls: a case–control study

et al. 2020

View full text Add to dashboard Cite

Background Since evidence-based dietary guidelines are lacking for IBD patients, they tend to follow "unguided" dietary habits; potentially leading to nutritional deficiencies and detrimental effects on disease course. Therefore, we compared dietary intake of IBD patients with controls. Methods Dietary intake of macronutrients and 25 food groups of 493 patients (207 UC, 286 CD), and 1291 controls was obtained via a food frequency questionnaire. Results 38.6% of patients in remission had protein intakes below the recommended 0.8 g/kg and 86.7% with active disease below the recommended 1.2 g/kg. Multinomial logistic regression, corrected for age, gender and BMI, showed that (compared to controls) UC patients consumed more meat and spreads, but less alcohol, breads, coffee and dairy; CD patients consumed more non-alcoholic drinks, potatoes, savoury snacks and sugar and sweets but less alcohol, dairy, nuts, pasta and prepared meals. Patients with active disease consumed more meat, soup and sugar and sweets but less alcohol, coffee, dairy, prepared meals and rice; patients in remission consumed more potatoes and spreads but less alcohol, breads, dairy, nuts, pasta and prepared meals. Conclusions Patients avoiding potentially favourable foods and gourmandizing potentially unfavourable foods are of concern. Special attention is needed for protein intake in the treatment of these patients.

show abstract

“…Both cell types acquired an inflammatory phenotype characterized by a sustained inflammatory cascade that was orchestrated by the transcription factors NF-κB and STAT3. Indeed, our experimental model is a slight modification of a previous published bioassay for oral mucositis [15]. However, we used LPS to trigger the inflammatory phenotype instead of recombinant cytokines, as in the previously published model [22].…”

Section: Discussionmentioning

confidence: 99%

“…Relevant bioassays are therefore needed to facilitate the preclinical screening of candidate molecules. In this context, human gingival fibroblasts (GF) and human oral mucosa epithelial cells (EC) with an inflammatory phenotype represent a valuable experimental paradigm to explore the potential curative activity of agents to be used in this clinical condition [15]. LPS boosts an inflammatory cascade that plays a pivotal role in the pathogenesis of this unpleasant disease.…”

Section: Introductionmentioning

confidence: 99%

β-Caryophyllene Reduces the Inflammatory Phenotype of Periodontal Cells by Targeting CB2 Receptors

et al. 2020

View full text Add to dashboard Cite

Human gingival fibroblasts (GF) and human oral mucosa epithelial cells (EC) with an inflammatory phenotype represent a valuable experimental paradigm to explore the curative activity of agents to be used in oral mucositis. The role of cannabinoid receptor 2 (CB2) has not yet been investigated in oral mucositis. The aim of this study was to evaluate the therapeutic potential of β-Caryophyllene (BCP), a CB2 agonist, in an in vitro model of oral mucositis. GF and EC were stimulated with LPS (2 µg/mL) alone or in combination with BCP; a group of LPS challenged GF and EC were treated with BCP and AM630, a CB2 antagonist. LPS increased the inflammatory cytokines TNF-α, IL-1β, IL-6 and IL-17A whereas it decreased the anti-inflammatory cytokine IL-13. The upstream signals were identified in an augmented expression of NF-κB and STAT-3 and in reduced mRNA levels of PPARγ and PGC-1α. BCP blunted the LPS-induced inflammatory phenotype and this effect was reverted by the CB2 antagonist AM630. These results suggest that CB2 receptors are an interesting target to develop innovative strategies for oral mucositis and point out that BCP exerts a marked curative effect in a preclinical model of oral mucositis which deserves to be confirmed in a clinical setting.

show abstract

The anti-inflammatory effect of milk and dairy products on periodontal cells: an in vitro approach

Abstract: Our in vitro findings provide the scientific basis to extend this research towards testing the anti-inflammatory effects of milk in a pre-clinical periodontitis and peri-implantitis model.

Cited by 23 publications

References 39 publications

Chemoprevention of DMH-Induced Early Colon Carcinogenesis in Male BALB/c Mice by Administration of Lactobacillus Paracasei DTA81

Chemoprevention of DMH-Induced Early Colon Carcinogenesis in Male BALB/c Mice by Administration of Lactobacillus Paracasei DTA81

Habitual dietary intake of IBD patients differs from population controls: a case–control study

β-Caryophyllene Reduces the Inflammatory Phenotype of Periodontal Cells by Targeting CB2 Receptors

Contact Info

Product

Resources

About